Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid

Hichul Kim, Victoria El-Khoury (Main author), Nadine Schulte, Tianzuo Zhan, Johannes Betge, Loic Cousin, Emanuele Felli, Patrick Pessaux, Arnaud Ogier, Oliver Opitz, Bosung Ku, Matthias P. Ebert, Yong Jun Kwon*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in ex-vivo spheroids obtained from the patient's liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment.

Original languageEnglish
Pages (from-to)96-102
Number of pages7
JournalCancer Biology and Therapy
Volume23
Issue number1
DOIs
Publication statusPublished - 31 Dec 2022

Keywords

  • antiangiogenic therapy
  • drug screening
  • lung carcinoid
  • neuroendocrine tumors
  • Personalized functional profiling
  • personalized medicine
  • pharmacotyping
  • precision medicine
  • spheroids

Fingerprint

Dive into the research topics of 'Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid'. Together they form a unique fingerprint.

Cite this